Genomed Spólka Akcyjna

Equities

GEN

PLGNOMD00024

Biotechnology & Medical Research

End-of-day quote Warsaw S.E. Other stock markets 03:30:00 02/07/2024 am IST			5-day change	1st Jan Change
28 ^PLN	0.00%		0.00%	-6.04%

13/05	Genomed Spólka Akcyjna Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
14/02	Genomed Spólka Akcyjna Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI

Diagnostyka Sp. z o.o. completed the acquisition of an unknown stake in Genomed Spólka Akcyjna from MCI.Credit Ventures 2.0 FIZ of MCI Capital TFI SA.

June 11, 2018

Diagnostyka Sp. z o.o. made an offer to acquire an unknown stake in Genomed Spólka Akcyjna (WSE:GEN) from MCI.Credit Ventures 2.0 FIZ of MCI Capital TFI SA on May 28, 2018. Diagnostyka Sp. z o.o. completed the acquisition of an unknown stake in Genomed Spólka Akcyjna (WSE:GEN) from MCI.Credit Ventures 2.0 FIZ of MCI Capital TFI SA on June 11, 2018.

Latest news about Genomed Spólka Akcyjna

Genomed Spólka Akcyjna Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05	CI
Genomed Spólka Akcyjna Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	14/02	CI
Genomed Spólka Akcyjna Reports Earnings Results for the Full Year Ended December 31, 2023	14/02	CI
Genomed Spólka Akcyjna Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
Genomed Spólka Akcyjna Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Genomed Spólka Akcyjna Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
Genomed Spólka Akcyjna Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	14/23/14	CI
Genomed Spólka Akcyjna Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/22/15	CI
Genomed Spólka Akcyjna Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/22/12	CI
Genomed Spólka Akcyjna Reports Earnings Results for the First Quarter Ended March 31, 2022	13/22/13	CI
Genomed Spólka Akcyjna Reports Earnings Results for the Second Quarter Ended June 30, 2021	13/21/13	CI
Genomed Spólka Akcyjna Reports Earnings Results for the First Quarter Ended March 31, 2021	14/21/14	CI
Genomed Spólka Akcyjna Reports Earnings Results for the Fourth Quarter Ended December 31, 2020	12/21/12	CI
Diagnostyka Sp. z o.o. completed the acquisition of an unknown stake in Genomed Spólka Akcyjna from MCI.Credit Ventures 2.0 FIZ of MCI Capital TFI SA.	11/18/11	CI
Diagnostyka Sp. z o.o. made an offer to acquire an unknown stake in Genomed Spólka Akcyjna from MCI.Credit Ventures 2.0 FIZ of MCI Capital TFI SA.	28/18/28	CI

Chart Genomed Spólka Akcyjna

Duration

Period

More charts

Company Profile

Genomed SA is a Poland-based company engaged in genetic research. It develops molecular diagnostics based on deoxyribonucleic acid (DNA) sequencing, with a special focus on the Next Generation Sequencing (NGS) method. The Companyâs offer includes the analysis of gene mutations responsible for over 150 congenital diseases, such as infertility, predisposition to cancer, cystic fibrosis (CF), Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy and obesity, among others. The Companyâs activities are directed toward introducing genomic technology to personalized medicine and creating a clinic offering gene treatments. The Company also provides diverse DNA sequencing, analysis and synthesis services for research and the biotechnological market.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
GENOMED SPÓLKA AKCYJNA	-6.04%	9.21M
MODERNA, INC.	+16.59%	44.87B
IQVIA HOLDINGS INC.	-10.62%	37.8B
LONZA GROUP AG	+40.49%	37.61B
ALNYLAM PHARMACEUTICALS, INC.	+29.92%	31.32B
CELLTRION, INC.	-9.78%	27.4B
ICON PUBLIC LIMITED COMPANY	+12.34%	26.32B
UNITED THERAPEUTICS CORPORATION	+41.53%	14.07B
MEDPACE HOLDINGS, INC.	+31.49%	12.5B
BIO-TECHNE CORPORATION	-7.40%	11.23B

Other Biotechnology & Medical Research